SCHEMBL862126

SCHEMBL862126

CS(=O)(=O)NC(=O)c1c(-c2ccc[nH]c2=O)c2cc(Cl)ccc2n1CCCF

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40
APH1A Q96BI3 1/20 0.40
PSENEN Q9NZ42 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
HPGD P15428 1/20 0.40
CYP2C8 P10632 1/20 0.38
CHEK1 O14757 3/20 0.38
CDK1 P06493 1/20 0.38
WEE1 P30291 1/20 0.38
MCL1 Q07820 2/20 0.38
KMT2A Q03164 1/20 0.37
PTGDR2 Q9Y5Y4 4/20 0.36
SCN9A Q15858 3/20 0.35
SCN2B O60939 2/20 0.34
SCN1B Q07699 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL831509 0.93 PSEN1 (0.45) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL831574 0.91 KDM4E (0.41) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL831565 0.89 ALDH1A1 (0.40) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL862476 0.88 PPARG (0.36) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL862037 0.88 KMT2A (0.44) KDM4EALDH1A1CYP1A2HPGDCYP2C8
SCHEMBL862181 0.87 PTGDR2 (0.46) KDM4EALDH1A1CYP1A2HPGDCYP2C8
SCHEMBL832199 0.87 CYP2C8 (0.46) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL862375 0.87 KMT2A (0.44) KDM4EALDH1A1CYP1A2HPGDCYP2C8
SCHEMBL862067 0.87 KMT2A (0.50) KDM4EALDH1A1CYP1A2HPGDCYP2C8
SCHEMBL831170 0.87 KDM4E (0.38) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 PSEN1 1834/4885PSEN2 659/4885APH1B 4032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.